A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma

Nao Suzuki, Daisuke Aoki, Shinji Oie, Miwa Horiuchi, Yuko Hasegawa, Sachiko Ezawa, Atsushi Suzuki, Nobuyuki Susumu, Fumihito Hosoi, Kenji Kitazato, Shiro Nozawa

Research output: Contribution to journalArticle

11 Citations (Scopus)


Objectives. A novel retinobenzoic acid derivative, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), was reported to suppress the growth and invasion of human gastric cancer or hepatocellular carcinoma by induction of apoptosis. We examined the antitumor activity of TAC-101 against human ovarian carcinoma cell lines. Methods. Apoptosis of human epithelial ovarian carcinoma-derived cell lines (RMG-I, RMG-II, RTSG, RMUG-S, RMUG-L, and KF) was investigated by detecting DNA laddering and was quantified by an enzyme-linked immunosorbent assay. Inhibition of apoptosis was also examined using a caspase inhibitor. Furthermore, TAC-101 (8 mg kg-1 day -1 orally for 30 days) was investigated in nude mice with subcutaneous RMG-II tumors. A prominent apoptotic response to TAC-101 was observed. The antitumor effects of cisplatin (7 mg/kg intravenously on day 1) and paclitaxel (36 mg/kg intravenously on days 1 and 5) were also assessed for comparison. Results. Apoptosis occurred in all of the cell lines (except KF) in a concentration-dependent manner after exposure to TAC-101 and was markedly induced in RMG-I and RMG-II cells (derived from ovarian clear cell adenocarcinomas). A caspase inhibitor blocked the induction of apoptosis by TAC-101. The maximum inhibition of RMG-II tumor growth in nude mice by TAC-101, cisplatin, and paclitaxel was 45%, 34%, and 47%, respectively. Conclusion. Oral TAC-101 shows potential as a novel antitumor agent for ovarian carcinoma, especially ovarian clear cell adenocarcinoma.

Original languageEnglish
Pages (from-to)643-649
Number of pages7
JournalGynecologic Oncology
Issue number3
Publication statusPublished - 2004 Sep 1



  • Apoptosis
  • Clear cell adenocarcinoma
  • Ovarian carcinoma
  • Synthetic retinoid
  • TAC-101

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this